

CURRICULUM VITAE

Anna JANSEN

Pediatric Neurology Unit | VUB – UZ Brussel
Laarbeeklaan 101 | 1090 Brussel
Tel: +32 2 477 57 85 | Fax: +32 2 477 57 86
Email: anna.jansen@vub.ac.be

Personal

Born in Wilrijk on August 5, 1974
Married, three children
Belgian Nationality

Current Academic Position

2009 – present: Research Professor, Vrije Universiteit Brussel
Department of Health Sciences
Research Cluster Reproduction, Genetics and Regenerative Medicine
Research Cluster Mental Health and Wellbeing

Current Clinical Position

2011 – present: Head of Clinics, Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel

Previous Clinical Positions

2007 – 2011: Junior Staff member, Pediatric Neurology Unit, UZ Brussel

Studies

2007 – 2008: PhD in Medical Sciences, VUB
2005 – 2006: Postgraduate training in Pediatric Neurology, UZ Brussel
1999 – 2004: Postgraduate training in Neurology
UZ Brussel Departments of Neurology and Internal Medicine (1999 – 2003)
University of Antwerp, Department of Molecular Genetics (2003)
1992 – 1999: Medical School, University of Antwerp and Université Rennes 1 (Master 2)

Fellowship

2003 – 2004 Neurogenetics Unit, Montreal Neurological Hospital and Institute, McGill University, Montreal, Canada (Eva and Frederick Andermann)

Papers in international peer-reviewed journals

Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, **Jansen AC**; TOSCA consortium and TOSCA investigators. Tuberous Sclerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. *Orphanet J Rare Dis.* 2017 Jan 5;12(1):2 (IF 3.290)

Tanyaçin I, Stouffs K, Daneels D, Al Assaf C, Lissens W, Jansen A, Gheldof A. Convert your favorite protein modeling program into a mutation predictor: "MODICT". *BMC Bioinformatics.* 2016 Oct 19;17(1):425. (IF 2.435)

Sys M, Van Den Bogaert A, Roosens B, Lampo A, **Jansen A**, Wouters S, Keymolen K. Can clinical characteristics be criteria to perform chromosomal microarray-analysis in children and adolescents with autism spectrum disorders? *Minerva Pediatr.* 2016 Sep 8. [Epub ahead of print] (IF 0.532)

Squier W, Mack J, **Jansen AC**. Infants dying suddenly and unexpectedly share demographic features with infants who die with retinal and dural bleeding: a review of neural mechanisms. *Dev Med Child Neurol.* 2016 Jul 20. doi: 10.1111/dmcn.13202 (IF 3.615)

Hardies K, Cai Y, Jardel C, **Jansen AC**, Cao M, May P, Djémié T, Hachon Le Camus C, Keymolen K, Deconinck T, Bhambhani V, Long C, Sajan SA, Helbig KL; AR working group of the EuroEPINOMICS RES Consortium, Suls A, Balling R, Helbig I, De Jonghe P, Depienne C, De Camilli P, Weckhuysen S. Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline. *Brain.* 2016 Sep;139(Pt 9):2420-30 (IF 10.103)

Leyder M, Vorsselmans A, Done E, Van Berkel K, Faron G, Foulon I, Naessens A, **Jansen A**, Foulon W, Gucciardo L. Primary maternal cytomegalovirus infections: accuracy of fetal ultrasound for predicting sequelae in offspring. *Am J Obstet Gynecol.* 2016 Nov;215(5):638.e1-638.e8

Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, **Jansen A**, Józwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. *Drugs.* 2016 Apr;76(5):551-65 (IF 4.343)

Curatolo P, Aronica E, **Jansen A**, Jansen F, Kotulska K, Lagae L, Moavero R, Jozwiak S. Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. *Eur J Paediatr Neurol.* 2016 Mar;20(2):203-11 (IF 2.301)

Tanyalcin I, Al Assaf C, Gheldof A, Stouffs K, Lissens W, **Jansen AC**. I-PV: a CIRCOS module for interactive protein sequence visualization. *Bioinformatics*. 2016 Feb 1;32(3):447-9 (IF 4.981)

Jansen AC, Robitaille Y, Honavar M, Mullatti N, Leventer RJ, Andermann E, Andermann F, Squier W. The histopathology of polymicrogyria: a series of 71 brain autopsy studies. *Dev Med Child Neurol*. 2016 Jan;58(1):39-48. (IF 3.29)

Bissay V, Van Malderen SC, Keymolen K, Lissens W, Peeters U, Daneels D, **Jansen AC**, Pappaert G, Brugada P, De Keyser J, Van Dooren S. SCN4A variants and Brugada syndrome: phenotypic and genotypic overlap between cardiac and skeletal muscle sodium channelopathies. *Eur J Hum Genet*. 2016 Mar;24(3):400-7.(IF 4.22)

de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M, **Jansen A**. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist. *Pediatric Neurology, Pediatr Neurol*. 2015 Jan;52(1):25-35 (IF 1.504)

Leclezio L, **Jansen A**, Whittemore VH, de Vries P. Pilot validation of the Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) Checklist. *Pediatric Neurology, Pediatr Neurol*. 2015 Jan;52(1):16-24 (IF 1.504)

Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, **Jansen AC**, Jozwiak S, Nabbout R, Sauter M, Touraine R, O Callaghan F, Zonnenberg B, Crippa S, Comis S, D Augères G, Belousova E, Carter T, Cottin V, Dahlin M, Ferreira J, Macaya A, Benedik M, Sander V, Youroukos S, Castellana R, Ulker B, Feucht M. TOSCA: first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. *Orphanet J Rare Dis*. 2014 Nov 26;9(1):182. (IF 3.96)

Squier W, **Jansen A**. Polymicrogyria: pathology, fetal origins and mechanisms. *Acta Neuropathol Commun*. 2014 Jul 22;2(1):80

Fieremans N, Bauters M, Belet S, Verbeeck J, **Jansen AC**, Seneca S, Roelens F, De Baere E, Marynen P, Froyen G. De novo MECP2 duplications in two females with intellectual disability and unfavorable complete skewed X-inactivation. *Hum Genet*. 2014 Nov;133(11):1359-67 (IF 4.522)

De Bruyn C, Vanderhasselt T, Tanyalçin I, Keymolen K, Van Rompaey KL, De Meirleir L, **Jansen AC**. Thin genu of the corpus callosum points to mutation in FOXP1 in a child with acquired microcephaly, trigonocephaly, and intellectual developmental disorder: A case report and review of literature. *Eur J Paediatr Neurol*. 2014 May;18(3):420-6 (IF 1.974)

Van Leynseele A, **Jansen A**, Goyens P, Martens G, Peeters S, Jonckheere A, De Meirleir L. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. *Eur J Pediatr*. 2013 Nov 14. [Epub ahead of print] (IF 1.907)

Djémié T, Weckhuysen S, Holmgren P, Hardies K, Van Dyck T, Hendrickx R, Schoonjans AS, Van Paesschen W, **Jansen AC**, De Meirleir L, Selim LA, Girgis MY, Buyse G, Lagae L, Smets K, Smouts I, Claeys KG, Van den Bergh V, Grisar T, Blatt I, Shorer Z, Roelens F, Afawi Z, Helbig I, Ceulemans B, De Jonghe P, Suls A. PRRT2 mutations: exploring the phenotypical boundaries. *J Neurol Neurosurg Psychiatry*. 2014 Apr;85(4):462-5 (IF 4.924)

Krueger DA, Northrup H, **International Tuberos Sclerosis Complex Consensus Group**. Tuberos sclerosis complex surveillance and management: recommendations of the 2012 International Tuberos Sclerosis Complex Consensus Conference. *Pediatr Neurol*. 2013 Oct;49(4):255-65. (IF 1.416)

Northrup H, Krueger DA, **International Tuberos Sclerosis Complex Consensus Group**. Tuberos sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberos sclerosis complex consensus conference. *Pediatr Neurol*. 2013 Oct;49(4):243-54. (IF 1.416)

De Waele L, Boon P, Ceulemans B, Dan B, **Jansen A**, Legros B, Leroy P, Delmelle F, Ossemann M, De Raedt S, Smets K, Van De Voorde P, Verhelst H, Lagae L. First line management of prolonged convulsive seizures in children and adults: good practice points. *Acta Neurol Belg*. 2013 Dec;113(4):375-80 (IF 0.466)

Tanyalçin I, Verhelst H, Halley DJJ, Vanderhasselt T, Villard L, Goizet C, Lissens W, Mancini GM, **Jansen AC**. Elaborating the phenotypic spectrum associated with mutations in ARFGEF2: case study and literature review. *Eur J Paediatr Neurol*, *Eur J Paediatr Neurol*. 2013 Nov;17(6):666-70 (IF 1.974)

Amrom D, Tanyalçin I, Verhelst H, Deconinck N, Brouhard GJ, Décarie JC, Vanderhasselt T, Das S, Hamdan F, Lissens W, Michaud J, **Jansen AC**. Polymicrogyria with dysmorphic basal ganglia? Think tubulin! *Clin Genet*. 2013 Mar 15. doi: 10.1111/cge.12141 (IF 3.128)

Handley MT, Morris-Rosendahl DJ, Brown S, Macdonald F, Hardy C, Bem D, Carpanini SM, Borck G, Martorell L, Izzi C, Faravelli F, Accorsi P, Pinelli L, Basel-Vanagaite L, Peretz G, Abdel-Salam GM, Zaki MS, **Jansen A**, Mowat D, Glass I, Stewart H, Mancini G, Lederer D, Roscioli T, Giuliano F, Plomp AS, Rolfs A, Graham JM, Seemanova E, Jackson IJ, Maher ER, Aligianis IA. Mutation Spectrum in RAB3GAP1, RAB3GAP2 and RAB18 and Genotype-Phenotype Correlations in Warburg Micro syndrome and Martsolf Syndrome. *Hum Mutat*. 2013;34(5):686-96 (IF 5.686)

Weckhuysen S, Holmgren P, Hendrickx R, **Jansen AC**, Hasaerts D, Dielman C, de Bellescize J, Boutry-Kryza N, Lesca G, Spiczak SV, Helbig I, Gill D, Yendle S, Møller RS, Klitten L, Korff C, Godfraind C, Van Rijkevorse K, De Jonghe P, Hjalgrim H, Scheffer IE, Suls A. Reduction of seizure frequency after epilepsy surgery in a patient with STXBP1 encephalopathy and clinical description of six novel mutation carriers. *Epilepsia*. 2013;54(5):e74-80 (IF 3.961)

van Harssel JJ, Weckhuysen S, van Kempen MJ, Hardies K, Verbeek NE, de Kovel CG, Gunning WB, van Daalen E, de Jonge MV, **Jansen AC**, Vermeulen RJ, Arts WF, Verhelst H, Fogarasi A, de Rijk-van Andel JF, Kelemen A, Lindhout D, De Jonghe P, Koeleman BP, Suls A, Brilstra EH. Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders. *Neurogenetics*. 2013 Feb;14(1):23-34 (IF 3.354)

Van Putten WK, Hachimi-Idrissi S, **Jansen A**, Van Gorp V, Huyghens L. Uncommon cause of psychotic behavior in a 9-year-old girl: a case report. *Case Rep Med*. 2012;2012:358520

Curatolo P, Jóźwiak S, Nabbout R; TSC Consensus Meeting for SEGA and Epilepsy Management. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. *Eur J Paediatr Neurol*. 2012 Nov;16(6):582-6 (IF 1.974)

Boon P, Engelborghs S, Hauman H, **Jansen A**, Lagae L, Legros B, Ossemann M, Sadzot B, Smets K, Urbain E, van Rijckevorsel K. Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update. *Acta Neurol Belg*. 2012 Jun;112(2):119-31 (IF 0.466)

Foulon I, Naessens A, Faron G, Foulon W, **Jansen AC**, Gordts F. Hearing thresholds in children with a congenital CMV infection: a prospective study. *Int J Pediatr Otorhinolaryngol*. 2012 May;76(5):712-7

Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, Deprez L, Smets K, Hristova D, Yordanova I, Jordanova A, Ceulemans B, Jansen A, Hasaerts D, Roelens F, Lagae L, Yendle S, Stanley T, Heron SE, Mulley JC, Berkovic SF, Scheffer IE, de Jonghe P. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. *Ann Neurol*. 2012 Jan;71(1):15-25 (IF 10.746)

Jansen AC, Oostra A, Desprechins B, De Vlaeminck Y, Verhelst H, Regal L, Verloo P, Bockaert N, Keymolen K, Seneca S, De Meirleir L, Lissens W. TUBA1A mutations: from isolated lissencephaly to familial polymicrogyria. *Neurology* 2011;76:988-992 (IF 8.017)

Squier W and **Jansen A**. Abnormal development of the human cerebral cortex. *J Anat*. 2010;217:312-23 (IF 2.410)

Deprez L, Weckhuysen S, Holmgren P, Suls A, Van Dyck T, Goossens D, Del Favero J, **Jansen A**, Verhaert K, Lagae L, Jordanova A, Van Coster R, Yendle S, Berkovic S, Scheffer I, Ceulemans B, De Jonghe P. Clinical spectrum of early onset epileptic encephalopathies associated with *STXBPI* mutations. *Neurology*. 2010;75:1159-65 (IF 8.017)

Leventer RJ, **Jansen A**, Pilz DT, Stoodley N, Marini C, Dubeau F, Malone J, Mitchell LA, Mandelstam S, Scheffer IE, Berkovic SF, Andermann E, Andermann F, Guerrini R, Dobyns WB. Clinical and imaging heterogeneity of polymicrogyria: a study of 328 patients. *Brain* 2010 May;133(Pt 5):1415-27 (IF 10.143)

Jansen AC. Cognitive deficits and developmental language disorders in patients with malformations of cortical development. *Epilepsia* 2010 Feb;51 Suppl 1:70-1 (IF 3.955)

Deprez L, **Jansen AC**, De Jonghe P. Genetics of epilepsy syndromes starting in the first year of life. *Neurology*, 2009;72:273-81 (IF 8.172)

Boon P, Engelborghs S, Hauman H, **Jansen A**, Lagae L, Legros B, Ossemann M, Sadzot B, Urbain E, van Rijckevorsel K. Recommendations for the treatment of epilepsies in general practice in Belgium. *Acta Neurol Belg*. 2008 Dec;108:118-30

Jansen AC, Andermann E, Niel F, Créveaux I, Boespflug-Tanguy O, Andermann F. Leucoencephalopathy with vanishing white matter may cause progressive myoclonus epilepsy. *Epilepsia*. 2008 May;49(5):910-3 (IF 3.733)

Jansen AC, Andermann E. Progressive Myoclonus Epilepsy, Lafora Type. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. *GeneReviews* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2007 Dec 28. PMID: 20301563

Jansen A, Cao H, Kaplan P, Silver K, Leonard G, De Meirleir L, Lissens W, Liebaers I, Veilleux M, Andermann F, Hegele RA, Andermann E. Sanfilippo syndrome type D: natural history and identification of three novel mutations in the *GNS* gene. *Arch Neurol*. 2007 Nov;64(11):1629-34 (IF 5.783)

Van Esch H, **Jansen A**, Bauters M, Froyen G, Fryns JP. Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the *CDKL5* and *NHS* genes. *Am J Med Genet A*. 2007;143:364-369 (IF 2.440)

Jansen A, Sancak O, D'Agostino MD, Badhwar A, Roberts P, Gobbi G, Wilkinson R, Melanson D, Tampieri D, Koenekoop R, Gans M, Li G, Seni H, Goedbloed M, van den Ouweland AMW, Nellist M, Pandolfo M, McQueen M, Sims K, Thiele E, Andermann F, Dubeau F, Kwiatkowski D, Halley DJJ, Andermann E. Unusually mild tuberous sclerosis phenotype is associated with *TSC2* R905Q mutation. *Annals of Neurology*, 2006;60:528-39 (IF 8.051)

Wieck G, Leventer R, Squier W, **Jansen A**, Andermann E, Dubeau F, Ramazzotti A, Guerrini R, Dobyns W. Periventricular nodular heterotopia with overlying polymicrogyria. *Brain* 2005;128:2811-2821 (IF 7.535)

Verhelst H, Boon P, Buyse G, Ceulemans B, D'Hooghe M, Meirleir LD, Hasaerts D, **Jansen A**, Lagae L, Meurs A, Coster RV, Vonck K. Steroids in intractable childhood epilepsy: clinical experience and review of the literature. *Seizure*. 2005;14:412-21

Al-Asmi A, **Jansen A**, Badhwar A, Dubeau F, Tampieri D, Shustik C, Mercho S, Savard G, Dobson-Stone C, Monaco A, Andermann F, Andermann E. Intractable Familial Temporal Lobe Epilepsy as a Presenting Feature of Chorea-Acanthocytosis. *Epilepsia*, 2005;46:1256-63 (IF 3.227)

Dobson-Stone C, Velayos-Baeza A, **Jansen A**, Andermann F, Dubeau F, Robert F, Summers A, Lang AE, Chouinard S, Danek A, Andermann E, Monaco AP. Identification of a *VPS13A* founder mutation in French Canadian families with chorea-acanthocytosis. *Neurogenetics*, 2005;6:151-8 (IF 2.938)

Jansen A and Andermann E. Genetics of the polymicrogyria syndromes. *J Med Genet*, 2005;42:369-78 (IF 4.330)

Kobayashi E, Bagshaw AP, **Jansen A**, Andermann F, Andermann E, Gotman J, Dubeau F. Intrinsic epileptogenicity in polymicrogyric cortex suggested by EEG-fMRI BOLD responses. *Neurology*, 2005;64:1263-6 (IF 5.065)

Jansen A, Leonard G, Festen J, Bastos AC, Tampieri D, Watkins K, Andermann F, and Andermann E. Cognitive functioning in bilateral perisylvian polymicrogyria. *Epilepsy and Behavior*, 2005;6:393-404 (IF 1.936)

Sheen V*, **Jansen A***, Ravenscroft R, Ganesh V, Underwood T, Wiley J, Leventer R, Vaid R, Hutchins G, Menasha J, Willner J, Rimmer W, Geng Y, Gripp K, Nicholson L, Berry-Kravis E, Bodell A, Apse K, Hill RS, Dubeau F, Andermann F, Barkovich J, Andermann E, Yao Y, Thomas P, Guerrini R, Walsh C. Ehlers-Danlos variant of periventricular heterotopia. *Neurology* 2005;64:254-62 (IF 5.065)

Badhwar A, **Jansen A**, Pandolfo M, Andermann F, Andermann E. Striking intra-familial phenotypic variability and spastic paraplegia in the presence of similar homozygous expansions of the *FRDA1* gene. *Movement Disorders*, 2004;19:1424-31 (IF 3.093)

Claes LRF, Ceulemans B, Audenaert D, Deprez L, **Jansen A**, Hasaerts D, Weckx S, Claeys KG, Del-Favero J, Van Broeckhoven C, and De Jonghe P. De novo *KCNQ2* mutations in patients with benign neonatal seizures. *Neurology*, 2004;63:2155-8 (IF 5.973)

Jansen A, Andermann E, and Andermann F. Biparental inheritance in idiopathic generalized epilepsy. *Epilepsia*, 2004;45:1294-5 (IF 3.329)

Lagae L, Buyse G, Ceulemans B, Claeys P, Dedeurwaerdere S, de Meirleir L, Hauman R, **Jansen A**, Schmedding E, Verhelst H, Vonck K. Anti-epileptogenesis research: the clinical relevance. *Acta Neurol Belg*. 2003;103:78-82

Jansen A, Velkeniers B. Neurological involvement in a case of hypophosphatemia. *Eur J Intern Med*. 2003;14:326-328.

Mercelis R, **Jansen A**, Martin JJ. Diagnostic aspects of myasthenia gravis. *Tijdschrift voor Geneeskunde* 2000;56:590-598

Book Chapters

Jansen AC. Lafora Disease. In: *The encyclopedia of Movement Disorders*. Kompoliti K, and Verhagen Metman L. (eds.) Oxford: Academic Press, 2010, vol 2,113-116

Jansen AC. Lafora body disease. In: *The Causes of Epilepsy*. Shorvon S, Guerrini R, Andermann F. Cambridge University Press; 1 edition (May 4, 2011): pp.143 - 146

Jansen AC. Neuroacanthocytosis. In: *The Causes of Epilepsy*. Shorvon S, Guerrini R, Andermann F. Cambridge University Press; 1 edition (May 4, 2011): pp. 212 - 215

Invited international lectures

2016

- Tuberos sclerosis: a multidisciplinary approach to the management of the children. Moscow, Russia (international teleconference)
- TSC - Burden of Disease and Challenges to Implementation of Care. International Tuberos Sclerosis Conference, Lisbon, Portugal
- TSC Associated Neuropsychiatric Disorders (TAND): early detection and clinical management. Enfermedades Neurocutáneas, Barcelona, Spain
- Treating Neuropsychiatric aspects of TSC (TAND). TSC days - Evolving the Treatment Paradigm in TSC to Optimize Patient Care. Frankfurt, Germany.
- TSC-geassocieerde neuropsychiatrische aandoeningen – het gebruik van de TAND-lijst. STSN Lustrum Symposium, Rotterdam, The Netherlands
- John Stobo Prichard Award Lecture: Developmental brain malformations. International Child Neurology Association. Amsterdam, the Netherlands
- EPISTOP - early treatment of epilepsy in TSC. International meeting on sleep and epilepsy. Kempenhaeghe, the Netherlands
- Neurological aspects of tuberous sclerosis complex. Diagnosis and management. Portugese Meeting of Pediatric Neurology, Porto, Portugal

2015

- Developmental brain malformations. Joint meeting of the Belgian and Dutch associations of Pediatric Neurology, Tilburg, The Netherlands
- EEG in the work-up of epilepsy. Flemish league against epilepsy, Leuven, Belgium

- Atypical Neuroaxonal Dystrophy, European Society of Pediatric Neurology, Vienna, Austria
- Side effect of mTOR inhibitors. TSC Days, Budapest, Hungary
- Economic burden of TSC. International TSC research conference. Windsor, UK
- Malformations of cortical development, EURO-CNS course Amsterdam, the Netherlands

2014

- Epilepsy Mind and Brain, Brno: Neurodevelopmental aspects of polymicrogyria

2013

- European Pediatric Neurology Society, Brussels: Clinical and molecular work-up of microcephaly
- European Pediatric Neurology Society, Brussels: Clinical Guidelines for the Management of CNS Manifestations in Tuberous Sclerosis Complex
- Masterclass on Tuberous Sclerosis Complex, Venice: Diagnostic work-up in TSC

2012

- Epilepsy and Sleep - International Kempenhaeghe Meeting: New treatments in childhood epilepsy

2011

- European Pediatric Neurology Society, Cavtat: Clinical and genetic patterns in malformations of cortical development

2010

- Polymicrogyria workshop, Boston: neuropathological basis of polymicrogyria

Promoter of master thesis

2012 - VUB Faculty of Medicine and Pharmaceutical Sciences (2)

VUB Interuniversitaire ManaMa Jeugdgezondheidszorg (1)

2013 - VUB Faculty of Medicine and Pharmaceutical Sciences (2)

2014 - VUB Interuniversitaire ManaMa Jeugdgezondheidszorg (1)

2016 – VUB Interuniversitaire ManaMa Jeugdgezondheidszorg (2)

Promoter of PhD thesis

Malformations of Cortical Development

PhD Ibrahim Tanylçin 2011 - 2015

PhD Laura Vandervore 2015 - 2019

Funding: Scientific Fund Willy Gepts, UZOR, Stichting Marie-Marguerite Delacroix

EPISTOP: Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous sclerosis complex

PhD Chloë Scheldeman 2013 - 2017 (Joint PhD KUL-VUB)

Funding: FP7 – HEALTH-2013-INNOVATION-1

Care trajectory and scholastic future of childhood brain tumor survivors: inventory and exploration of possible management strategies.

PhD Stephanie Vanclooster

Funding: Fund Jeanne and Alice Van de Voorde (KBS) 2013 – 2017

Clinical Trials

2009-2010: Co-investigator

ESAI/Quintiles - E2090-E044-312: A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures.

2009 - 2014: Principal Investigator

Novartis : CRAD001M2301: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)

2012 – 2013: Principal Investigator

Novartis: CRAD001MIC02: EFFECTS Study: an open-label, multi-centre, expanded access study of everolimus in patients with subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)

2012 – 2014: Principal Investigator

UCB SP847: A multicenter, open-label study to investigate the safety, tolerability, and pharmacokinetics of lacosamide (LCM) oral solution (syrup) as adjunctive therapy in children with partial-onset seizures

2013 - 2014: Collaborator Academic Study

Genetic risk factors for chickenpox associated neurological complications

PI: Ogunjimi Benson UA, FWO

2013 – present: Principal Investigator, member of the Working Committee, Vice-Chair of the Scientific Advisory Board

Novartis: CRAD001MIC03: Tuberous Sclerosis registry to increase disease Awareness (TOSCA)

2012 – present: Principal Investigator

UCB SP848: An open-label extension study to determine safety, tolerability, and efficacy of long-term oral lacosamide (LCM) as adjunctive therapy in children with partial-onset seizures

2013 – present: Principal Investigator

UCB SP969: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in epilepsy subjects ≥ 4 years to < 17 years of age with partial-onset seizures – phase 3

2013 – present: Principal Investigator

UCB EP0034: A multicenter, open-label, long-term extension study to investigate the efficacy and safety of Lacosamide as adjunctive therapy in pediatric subjects with epilepsy with partial-onset seizures

2013 – present: Principal Investigator

Novartis CRAD001M2304: EXIST 3 A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures

2014 - present: Principal Investigator

Pfizer A0081041: A double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of pregabalin as adjunctive therapy in children 4 - 16 years of age with partial onset seizures

2014 - present: Principal Investigator

Pfizer A0081105: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial Of Pregabalin As Adjunctive Therapy In Pediatric And Adult Subjects With Primary Generalized Tonic-Clonic Seizures

2014 - present: Principal Investigator

Pfizer A0081042: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin as Adjunctive Therapy in Children 1 month through 3 years of age with Partial onset seizures

2014 - present: Principal Investigator

Pfizer A0081106: A 12-Month Open-Label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Children 1 Month To 16 Years Of Age With Partial Onset Seizures And Child And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

2014 - present: Principal Investigator

Novartis CRAD001M2305: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301 (EXIST-LT)

Membership of PhD jury panels

2011 - VUB Stefan Hardonk

Parents' perspective on the care trajectory of their congenitally deaf child

2012 - KUL Anne-Sophie Serruys

Antiepileptic natural product discovery using a zebrafish seizure model

2013 - ULB Anne Génin

Identification et caractérisation de CASC5 chez des patients atteints de microcéphalie primaire

2013 - VUB Marc Degalaen

Influence of postural control during gait in children with cerebral palsy

2014 - Erasmus Universiteit Rotterdam Marije Meuwissen

Genetic Causes of Cerebrovascular Disorders in Childhood

- 2015 - Leiden University Marcia N. Goddard
X marks the spot
- 2016 - Erasmus Universiteit Rotterdam Renske Oegema
Malformations of Cortical Development - Clinical and Genetic Characterization
- 2016 – Universiteit Antwerpen Anouk Van de Vel
Epileptic seizure detection in children and young adults in their home replacement environment

Ad-hoc reviewer

Scientific journals: Brain, European Journal of Pediatric Neurology, Seizure, Orphanet
Journal of Rare Diseases, Epilepsia, Neurogenetics,, Acta Neurologica Belgica,
Developmental Medicine and Child Neurology

Grant applications: IWT, Fondation Charcot, TS Alliance

Membership of scientific societies

Member of the Executive Committee of the Society for the Study of Behavioural Phenotypes
Vice-Chair TOSCA Scientific Advisory Board (Tuberous Sclerosis Registry to Increase Disease Awareness)

Member of NEUROMIG (COST Action – European Network on Brain Malformations)

President of the Belgian League against Epilepsy (BLE)

Treasurer of the Flemish League against Epilepsy (VLE)

Member of the Advisory Committee medical scientific research - King Baudouin Foundation

Member of the Belgian Society of Pediatric Neurology

Member of the Belgian Neurological Society

Member of the Vlaamse Vereniging voor Neurologie

Member of the European Pediatric Neurology Society

Member of the International Child Neurology Association

Member of the American Academy of Neurology

Member of the Vlaamse Wetenschappelijke Vereniging voor Jeugdgezondheidszorg

Awards

John Stobo Prichard Award - International Child Neurology Association, May 2016

VVN-Eli Lilly Award, 2007

Pfizer Educational Grant, January 2005

Savoy Foundation for Epilepsy Research, July 2004

Nominate of the Belgische Stichting Roeping/Fondation Belge de la Vocation, April 2003